HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IMP1338

has antineoplastic activity; structure in first source

Also Known As:

N-(4-(((9,10-dioxo-9,10-dihydro-1-anthracenyl)sulfonyl)amino)phenyl)-N-methylacetamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ahn, Jiyeon: 1 article (04/2016)
2.	Choi, Hyun Kyung: 1 article (04/2016)
3.	Hwang, Sang-Gu: 1 article (04/2016)
4.	Ryu, Hwani: 1 article (04/2016)
5.	Seo, Bitna: 1 article (04/2016)
6.	Son, A-Rang: 1 article (04/2016)
7.	Song, Jie-Young: 1 article (04/2016)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2016 - "To elucidate the cellular mechanism underlying the cytotoxicity of IMP1338, we examined the effect of IMP1338 on the cell cycle distribution and death of cancer cells. " 04/01/2016 - "The MTT cell viability assay showed that treatment with IMP1338 selectively inhibited HCT116, HCT116 p53(-/-), HT29, and A549 cancer cell proliferation compared to that of Beas2B normal epithelial cells. " 04/01/2016 - "The novel anthraquinone derivative IMP1338 induces death of human cancer cells by p53-independent S and G2/M cell cycle arrest."
2.	Colonic Neoplasms (Colon Cancer) 04/01/2016 - "We discovered a novel anthraquinone derivative, N-(4-[{(9,10-dioxo-9,10-dihydro-1-anthracenyl)sulfonyl}amino]phenyl)-N-methylacetamide (IMP1338), which was cytotoxic against the human colon cancer cells tested. "

Related Drugs and Biologics

1.	Anthraquinones
2.	N-methylacetamide